Plain-English translation of NCT07709494 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
United States
Phase
Safety & dosing
Sponsor
Revagenix, Inc.
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment target
~64 participants
Started
July 2026
Primary completion
June 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chrissy Morgenthaler
Revagenix, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.